Comparative Pharmacology
Head-to-head clinical analysis: FOVANE versus PAXIPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOVANE versus PAXIPAM.
FOVANE vs PAXIPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by inhibiting reuptake of serotonin at the synaptic cleft.
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
Adults: 10 mg orally twice daily.
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
None Documented
None Documented
Terminal half-life: 12-15 hours; clinical context: supports twice-daily dosing, steady-state achieved by day 3.
Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment.
Renal: 60% unchanged; fecal: 30% (as metabolites); biliary: 10%.
Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%.
Category C
Category C
Benzodiazepine
Benzodiazepine